SCHEMBL1656460

SCHEMBL1656460

C[C@H](CCC(=O)NO)[C@H]1CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHA2 P29317 6/20 0.82
GPBAR1 Q8TDU6 6/20 0.82
HSD17B10 Q99714 3/20 0.82
TDP1 Q9NUW8 3/20 0.82
AKR1B10 O60218 2/20 0.82
AKR1B1 P15121 2/20 0.82
LMNA P02545 2/20 0.82
EFNA1 P20827 1/20 0.82
PSEN1 P49768 1/20 0.82
PSEN2 P49810 1/20 0.82
APH1B Q8WW43 1/20 0.82
NCSTN Q92542 1/20 0.82
APH1A Q96BI3 1/20 0.82
PSENEN Q9NZ42 1/20 0.82
MEN1 O00255 1/20 0.82
KMT2A Q03164 1/20 0.82
USP2 O75604 2/20 0.76
CYP3A4 P08684 2/20 0.63
HIF1A Q16665 2/20 0.63
CYP2C9 P11712 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19953827 0.92 EPHA2 (0.78) EPHA2GPBAR1HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL190519 0.90 GPBAR1 (1.00) EPHA2GPBAR1HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL22871921 0.90 GPBAR1 (1.00) EPHA2GPBAR1HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL13811793 0.90 GPBAR1 (1.00) EPHA2GPBAR1HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL25021694 0.90 GPBAR1 (1.00) EPHA2GPBAR1HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL25023044 0.90 GPBAR1 (1.00) EPHA2GPBAR1HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL5556804 0.90 GPBAR1 (1.00) EPHA2GPBAR1HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL25023120 0.90 GPBAR1 (1.00) EPHA2GPBAR1HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL1688735 0.90 GPBAR1 (1.00) EPHA2GPBAR1HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL16084677 0.90 GPBAR1 (1.00) EPHA2GPBAR1HSD17B10TDP1AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1364645-A1 Pharmaceutical combinations for topical use based on iron chelators, metalloprotease inhibitors and factor XIII for the treatment of lipodermatosclerosis and trophic lesions of the cutaneous tissues and muccous membranes ZAMBONI, Paolo (IT) 2003-11-26 EP claimed
WO-1992016200-A1 THE USE OF HYDROXAMIC ACID DERIVATIVES TO INHIBIT VIRAL REPLICATION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) 1992-10-01 WO claimed
US-20140234398-A1 Dissolution of Arterial Plaque ATHERONOVA OPERATIONS, INC. (US) 2014-08-21 US disclosed
US-20140148422-A1 TREATMENT OF GLUCOSE INTOLERANCE ATHERONOVA OPERATIONS, INC. (US) 2014-05-29 US disclosed
US-20140142071-A1 REGRESSION OF ARTERIAL PLAQUE ATHERONOVA OPERATIONS, INC. (US) 2014-05-22 US disclosed
US-8697633-B2 Dissolution of arterial plaque ATHERONOVA OPERATIONS, INC. (US) 2014-04-15 US disclosed
US-20130029946-A1 DISSOLUTION OF ARTERIAL PLAQUE ATHERANOVA OPERATIONS, INC. (US) 2013-01-31 US disclosed
US-8304383-B2 Atherosclerosis therapy ; circulation of emulsifiers; using bile salts, saponins or detergent surfactant; concurrent administering with statin ATHERONOVA OPERATIONS, INC. (US) 2012-11-06 US disclosed
EP-2485738-A2 COMPOSITIONS AND METHODS FOR TREATING OBESITY Atheronova Operations, Inc. (US) 2012-08-15 EP disclosed
WO-2011044523-A2 COMPOSITIONS AND METHODS FOR TREATING OBESITY ATHERONOVA OPERATIONS, INC. (US) 2011-04-14 WO disclosed
US-20110086829-A1 COMPOSITIONS AND METHODS FOR TREATING OBESITY ATHERONOVA OPERATIONS, INC. 2011-04-14 US disclosed
US-20030153531-A1 Modified polysaccharides exhibiting altered biological recognition THERAPURE BIOPHARMA INC. (CA) 2003-08-14 US disclosed
US-6479468-B1 Modified polysaccharides exhibiting altered biological recognition BIOMEDICAL FRONTIERS, INC. 2002-11-12 US disclosed
EP-1037642-A1 MODIFIED POLYSACCHARIDES EXHIBITING ALTERED BIOLOGICAL RECOGNITION BIOMEDICAL FRONTIERS, INC. (US) 2000-09-27 EP disclosed
WO-1999029328-A1 MODIFIED POLYSACCHARIDES EXHIBITING ALTERED BIOLOGICAL RECOGNITION BIOMEDICAL FRONTIERS, INC. (US) 1999-06-17 WO disclosed
WO-1999008996-A1 METHOD OF REDUCING A SCHIFF BASE BIOMEDICAL FRONTIERS, INC. (US) 1999-02-25 WO disclosed
US-5847110-A Method of reducing a schiff base BIOMEDICAL FRONTIERS, INC. (US) 1998-12-08 US disclosed
WO-1998020905-A2 TREATMENT OF IRON OVERLOAD DISORDERS BIOMEDICAL FRONTIERS, INC. (US) 1998-05-22 WO disclosed
US-5646316-A ANTIMETASTASIS AND ANTITUMOR AGENTS OSTEOARTHRITIS SCIENCES, INC. (US) 1997-07-08 US disclosed
WO-1992016200-A1 THE USE OF HYDROXAMIC ACID DERIVATIVES TO INHIBIT VIRAL REPLICATION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) 1992-10-01 WO disclosed